Variant activin receptor
US9809638B2 · kind B2 · utility
22Cited by
60References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 2, 2016 |
| Grant date | Nov 7, 2017 |
| Priority date | — |
| Expiry date | Jun 2, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.